Wyeth Diet Drug Liability Outlook May Be Helped By FBI Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Philadelphia verdicts involving valvular disorder “opt out” claims are early successes for Wyeth, company says; plaintiffs’ lawyers ended up with “money losing proposition” in each of five cases. PPH cases, though relatively few in number, offer more uncertainty after $1 bil. verdict goes against Wyeth.
You may also be interested in...
Wyeth Fen/Phen Settlement Amendment May Require Additional Reserves
The number of Redux patients that opt into the "seventh amendment" to the diet drug litigation settlement will determine whether Wyeth has adequate legal reserves. The amendment creates a $1.275 bil. fund for fen/phen patients with less serious medical conditions.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.